The core research question was never addressed due to missing literature content. Identifying these specific modifications is critical for developing selective therapeutics that target disease-associated tau without disrupting normal tau function. Source: Debate session sess_SDA-2026-04-10-SDA-2026-04-09-gap-debate-20260409-201742-1e8eb3bd (Analysis: SDA-2026-04-09-gap-debate-20260409-201742-1e8eb3bd)
Landscape Summary: Which specific post-translational modifications distinguish pathological from physiological tau for therapeutic targeting? is a 0.9 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: partially_addressed.
Colonna, Sevlever, et al. (TREM2 biology)
Which specific post-translational modifications distinguish pathological from physiological tau for therapeutic targeting? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No knowledge graph edges recorded
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: